Detalhe da pesquisa
1.
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.
Cell
; 153(5): 1064-79, 2013 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-23706743
2.
Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Annu Rev Pharmacol Toxicol
; 64: 455-479, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738504
3.
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
Blood
; 139(8): 1208-1221, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34482403
4.
Functional genomic landscape of acute myeloid leukaemia.
Nature
; 562(7728): 526-531, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30333627
5.
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.
Br J Haematol
; 200(3): 323-328, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264026
6.
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.
Proc Natl Acad Sci U S A
; 117(25): 14331-14341, 2020 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32513686
7.
Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.
Clin Proteomics
; 19(1): 30, 2022 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35896960
8.
Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.
Blood
; 135(24): 2159-2170, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32315394
9.
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.
Invest New Drugs
; 39(3): 736-746, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33403501
10.
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Proc Natl Acad Sci U S A
; 114(36): E7554-E7563, 2017 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28784769
11.
Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.
J Biol Chem
; 293(32): 12502-12515, 2018 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29903916
12.
CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia.
Br J Haematol
; 202(1): 195-198, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182843
13.
Oncoproteomic profiling of AML: moving beyond genomics.
Expert Rev Proteomics
; 19(7-12): 283-287, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36734985
14.
Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens.
J Pediatr Hematol Oncol
; 39(7): e359-e366, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28906323
15.
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
N Engl J Med
; 368(19): 1781-90, 2013 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-23656643
16.
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Am J Hematol
; 96(7): E226-E229, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33780043
17.
Detecting and targetting oncogenic fusion proteins in the genomic era.
Biol Cell
; 107(5): 111-29, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25631473
18.
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
Proc Natl Acad Sci U S A
; 110(48): 19519-24, 2013 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24218589
19.
ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex.
Cancer Cell
; 12(6): 542-58, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18068631
20.
Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformation.
J Biol Chem
; 288(39): 27940-50, 2013 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-23798677